Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET) - Archive ouverte HAL Access content directly
Journal Articles Angiogenesis Year : 2020

Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET)

Antoine Vasseur
  • Function : Author
Olivier Trédan
Anthony Gonçalves
  • Function : Author
  • PersonId : 934200
Alexia Savignoni
  • Function : Author
  • PersonId : 901118

Abstract

Proof of concept studies has reported that circulating endothelial cell (CEC) count may be associated with the outcome of HER2-negative metastatic breast cancer (mBC) patients treated by chemotherapy and the anti-VEGF antibody bevacizumab. We report the results obtained in an independent prospective validation cohort (COMET study, NCT01745757).
Not file

Dates and versions

hal-02888436 , version 1 (03-07-2020)

Identifiers

Cite

Antoine Vasseur, Luc Cabel, Olivier Trédan, Marion Chevrier, Coraline Dubot, et al.. Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET). Angiogenesis, 2020, 23 (2), pp.193-202. ⟨10.1007/s10456-019-09697-7⟩. ⟨hal-02888436⟩
93 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More